Figure 3.

Importance of T cells, NK cells, and IFN-γ in gp96 vaccine–induced tumor protection. Mice (5 per group) were subcutaneously vaccinated twice with pooled heterologous gp96BCD and depleted of CD4⁺ or CD8⁺ T cells or NK cells by specific mAbs before tumor-A challenge, or IFNγ^−/− mice were subcutaneously vaccinated twice with gp96BCD and followed by tumor A challenge. Tumor burdens were measured twice each week. Mice were killed when subcutaneous tumors reached 225 mm² or when mice became moribund. Results shown are measurements of tumor burdens and survival of mice that received different treatments. Representative results of 1 of 2 independent experiments performed are shown. *P < .05; **P < .01 (compared with controls).